Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Price$15.60

Value ScoreB

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)2.75%

Price vs S&P 500 (4W)-4.56%

VGM Score57.06

Market Capitalization$48.01B

P/E Ratio (Annual)40.09x

Indicated Dividend Yield (Annual)4.14%

All Metrics

P/CF (Annual)7.38x

Book Value / Share (Quarterly)$30.73

P/TBV (Annual)2.07x

Indicated Dividend (Annual)$1.27

Revenue Growth (3Y)3.81%

Cash Flow / Share (Quarterly)$2.49

Payout Ratio (TTM)129.16%

Price vs S&P 500 (YTD)-5.09%

Gross Margin (TTM)65.12%

Net Profit Margin (TTM)4.26%

EPS (TTM)$0.76

10-Day Avg Trading Volume4.82M

EPS Excl Extra (TTM)$0.76

Revenue Growth (5Y)7.10%

EPS (Annual)$0.76

Dividend / Share (Annual)$1.24

ROI (Annual)1.52%

Gross Margin (Annual)65.12%

Net Profit Margin (5Y Avg)4.86%

Cash / Share (Quarterly)$2.52

P/E Basic Excl Extra (TTM)40.09x

Revenue Growth QoQ (YoY)3.91%

EPS Growth (5Y)-12.62%

P/E Normalized (Annual)40.09x

ROA (Last FY)1.24%

Revenue Growth TTM (YoY)-1.66%

EBITD / Share (TTM)$3.81

ROE (5Y Avg)3.01%

Operating Margin (TTM)9.07%

Cash Flow / Share (Annual)$2.49

P/B Ratio0.99x

P/B Ratio (Quarterly)1.16x

Net Income / Employee (Annual)$25,233

EV / Revenue (TTM)2.66x

Net Interest Coverage (TTM)2.75x

ROA (TTM)1.29%

EPS Growth QoQ (YoY)337.18%

EV / EBITDA (TTM)12.47x

EPS Incl Extra (Annual)$0.76

Current Ratio (Annual)1.27x

Quick Ratio (Quarterly)0.70x

3-Month Avg Trading Volume4.70M

52-Week Price Return5.51%

EV / Free Cash Flow (Annual)18.99x

P/E Incl Extra (TTM)40.09x

Revenue / Employee (TTM)$592,883

Tangible BV / Share (Quarterly)$17.21

P/S Ratio (Annual)1.71x

Asset Turnover (Annual)0.29x

52-Week High$6033.00

Operating Margin (5Y Avg)9.68%

EPS Excl Extra (Annual)$0.76

CapEx CAGR (5Y)11.69%

Tangible BV CAGR (5Y)28.07%

26-Week Price Return10.67%

Quick Ratio (Annual)0.70x

13-Week Price Return-14.98%

Total Debt / Equity (Annual)0.63x

Current Ratio (Quarterly)1.27x

Enterprise Value$74.78B

Revenue / Share Growth (5Y)7.08%

Asset Turnover (TTM)0.30x

Book Value / Share Growth (5Y)8.26%

Revenue / Employee (Annual)$592,883

Inventory Turnover (Annual)1.20x

Pretax Margin (Annual)5.77%

Cash / Share (Annual)$2.52

3-Month Return Std Dev23.45%

Gross Margin (5Y Avg)67.05%

Net Income / Employee (TTM)$25,233

EBITDA CAGR (5Y)0.38%

EBITDA Interim CAGR (5Y)-11.82%

ROE (Last FY)2.47%

Net Interest Coverage (Annual)2.75x

EPS Basic Excl Extra (Annual)$0.76

P/FCF (TTM)12.19x

Receivables Turnover (TTM)6.02x

EV / Free Cash Flow (TTM)18.99x

Total Debt / Equity (Quarterly)0.63x

EPS Incl Extra (TTM)$0.76

Receivables Turnover (Annual)6.02x

ROI (TTM)1.59%

Dividend Growth Rate (5Y)1.73%

P/S Ratio (TTM)1.71x

Pretax Margin (5Y Avg)5.72%

Revenue / Share (Annual)$17.86

Tangible BV / Share (Annual)$17.21

Forward P/E35.89x

Free OCF CAGR (5Y)-4.03%

Price vs S&P 500 (52W)-12.10%

P/E Ratio (TTM)40.09x

EPS Growth TTM (YoY)82.79%

Year-to-Date Return1.88%

5-Day Price Return0.92%

EPS Normalized (Annual)$0.76

ROA (5Y Avg)1.39%

Net Profit Margin (Annual)4.26%

Month-to-Date Return-3.75%

Cash Flow / Share (TTM)$3.51

EBITD / Share (Annual)$4.13

EPS Growth (3Y)-15.52%

Operating Margin (Annual)9.07%

LT Debt / Equity (Annual)0.56x

P/CF (TTM)7.38x

ROI (5Y Avg)1.78%

P/E Excl Extra (TTM)40.09x

LT Debt / Equity (Quarterly)0.56x

EPS Basic Excl Extra (TTM)$0.76

P/TBV (Quarterly)2.07x

Payout Ratio (Annual)162.65%

P/B Ratio (Annual)1.16x

Dividend / Share (TTM)$1.24

Inventory Turnover (TTM)1.20x

Pretax Margin (TTM)5.77%

Book Value / Share (Annual)$30.73

Price vs S&P 500 (13W)-23.24%

Net Margin Growth (5Y)-18.38%

Dividend Yield (TTM)4.06%

Beta0.42x

P/FCF (Annual)12.19x

Revenue / Share (TTM)$17.81

ROE (TTM)2.61%

52-Week Low$4102.00

vGradeB

gGradeC

mGradeC

vgmGradeC

Show chart for

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

3.74

3.95

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	B	C	C	$15.60
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Japan's largest pharmaceutical company with JPY 4.6 trillion in fiscal 2024 revenue. Takeda derives over 80% of sales from five core therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. Geographic revenue is well-diversified across the US (over 50%), Japan (20%), and Europe/Canada (20%).